The NDUFA13 gene (also known as GRIM-19) encodes a crucial subunit of mitochondrial complex I (NADH:ubiquinone oxidoreductase), the largest complex of the mitochondrial electron transport chain. NDUFA13 plays a dual role in cellular physiology: it is essential for the structural integrity and function of complex I, and it serves as a pro-apoptotic gene product involved in cell death regulation. This gene has garnered significant attention in neurodegenerative disease research due to its critical role in mitochondrial oxidative phosphorylation and its involvement in programmed cell death pathways.
NDUFA13 was originally identified as GRIM-19 (GRIM-19: Gene associated with Retinoid-Interferon-induced Mortality-19), a gene induced by the combination of interferon-β and retinoic acid that sensitizes cancer cells to TRAIL-induced apoptosis [1]. Subsequent research revealed that GRIM-19 is a fundamental subunit of mitochondrial complex I, where it plays an essential role in electron transfer and proton pumping.
Mitochondrial complex I (NADH:ubiquinone oxidoreductase) is the largest enzyme of the mitochondrial respiratory chain, comprising 45 subunits and catalyzing the transfer of electrons from NADH to ubiquinone while pumping protons across the inner mitochondrial membrane [2]. This process is crucial for ATP synthesis and cellular energy production. Complex I deficiency is one of the most common causes of mitochondrial diseases, often presenting with severe neurological manifestations including Leigh syndrome, cardiomyopathy, and developmental delays.
The relevance of NDUFA13 to neurodegenerative diseases extends beyond its role in oxidative phosphorylation. Its dual function as both a structural component of complex I and a regulator of apoptosis places it at the intersection of energy metabolism, oxidative stress, and cell death—all processes central to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related disorders.
NDUFA13 is a nuclear-encoded mitochondrial protein that assembles into the peripheral arm of complex I [3]. The protein is located in the N-module of complex I, which is responsible for NADH oxidation. As part of the electron transfer chain, NDUFA13 contributes to the structural stability of the complex and participates in the electron transfer pathway from NADH to ubiquinone.
The atomic structure of mammalian complex I has revealed the precise arrangement of all subunits, including NDUFA13, and has illuminated the mechanism of proton pumping [3:1]. The complex I machinery comprises multiple functional modules: the N-module (NADH dehydrogenase module), the Q-module (ubiquinone reduction module), and the P-modules (proton pumping modules). NDUFA13 is involved in the structural organization of these modules and the coupling of electron transfer to proton translocation.
Proper assembly of complex I requires the coordinated expression of both mitochondrial-encoded and nuclear-encoded subunits. NDUFA13 is synthesized in the cytoplasm and imported into mitochondria, where it assembles with other subunits to form the mature complex [4]. The assembly process involves multiple intermediate complexes and assembly factors that ensure proper subunit composition and stoichiometry.
Mutations in NDUFA13 that disrupt complex I assembly lead to reduced complex I activity and impaired mitochondrial respiration. This has been documented in patients with mitochondrial complex I deficiency and in cellular models carrying NDUFA13 mutations [5].
Beyond its role in oxidative phosphorylation, NDUFA13 (GRIM-19) functions as a pro-apoptotic regulator. The protein was originally identified in a genetic screen for genes that sensitize cells to apoptosis induced by the combination of interferon-β and retinoic acid [6]. GRIM-19 localizes to both mitochondria and the nucleus, where it can influence cell survival through multiple mechanisms:
The balance between NDUFA13's dual functions—energy production and apoptosis regulation—likely determines its net effect on cellular survival. In neurodegenerative diseases, where both energy failure and excessive neuronal apoptosis are features, NDUFA13 dysfunction may contribute to disease pathogenesis through both mechanisms.
As a core component of complex I, NDUFA13 is essential for the proper function of mitochondrial oxidative phosphorylation. Complex I catalyzes the first step in the respiratory chain, oxidizing NADH to NAD+ and transferring electrons to ubiquinone. This electron transfer is coupled to the pumping of four protons from the matrix to the intermembrane space, creating the electrochemical gradient that drives ATP synthesis.
The rate of complex I activity is tightly regulated by cellular energy demand and the availability of substrates. NDUFA13's presence in the complex is crucial for maintaining optimal electron transfer kinetics and preventing electron leak that could lead to excessive reactive oxygen species (ROS) production [7].
NDUFA13 mutations have been identified as a cause of mitochondrial complex I deficiency, a heterogeneous group of disorders characterized by impaired complex I function [5:1]. Clinical manifestations include:
The identification of NDUFA13 mutations in patients with complex I deficiency underscores the importance of this subunit for proper complex I assembly and function.
Complex I dysfunction has been documented in Alzheimer's disease (AD) brains, and several mechanisms may link NDUFA13 to AD pathogenesis [9]:
Mitochondrial Dysfunction: Early deficits in mitochondrial function are observed in AD, including reduced complex I activity. These deficits contribute to neuronal energy failure and synaptic dysfunction.
Oxidative Stress: Complex I dysfunction can lead to increased ROS production, contributing to the oxidative stress observed in AD brains. NDUFA13, as a structural component of complex I, may be affected by or contribute to this process.
Apoptosis: The pro-apoptotic function of NDUFA13 may be relevant to the excessive neuronal loss observed in AD. Dysregulation of apoptosis-controlling proteins is a feature of AD pathogenesis.
Amyloid-β Effects: Amyloid-β can directly impair mitochondrial function, including complex I activity. This interaction may involve effects on NDUFA13 and other complex I subunits.
Complex I deficiency is a well-established feature of Parkinson's disease (PD), particularly in the substantia nigra where dopaminergic neurons are selectively lost [10]:
Complex I Inhibition: Mitochondrial complex I activity is reduced in PD brains and in models of PD. This deficiency contributes to dopaminergic neuron vulnerability.
Oxidative Stress: Complex I dysfunction leads to increased ROS production, which may contribute to the oxidative damage observed in PD brains.
Mitochondrial DNA Mutations: Accumulation of mitochondrial DNA mutations in complex I genes has been documented in PD, including potentially in NDUFA13.
Alpha-Synuclein: The pathological protein in PD, alpha-synuclein, can impair mitochondrial function including complex I activity.
NDUFA13 dysfunction may also be relevant to other neurodegenerative conditions characterized by mitochondrial dysfunction:
NDUFA13 is widely expressed in human tissues, with particularly high expression in energy-demanding tissues including brain, heart, and skeletal muscle. Within the brain, NDUFA13 expression is detected in multiple regions:
The hippocampus, critical for learning and memory and severely affected in AD, shows high NDUFA13 expression. This reflects the high energy demands of hippocampal neurons and their dependence on mitochondrial oxidative phosphorylation.
The substantia nigra pars compacta, where dopaminergic neurons are lost in PD, expresses NDUFA13. The selective vulnerability of these neurons may relate to their high metabolic demands and particular sensitivity to complex I dysfunction.
Cerebral cortical neurons express NDUFA13, supporting their high energy requirements for synaptic activity and information processing.
Cerebellar Purkinje cells and other cerebellar neurons express NDUFA13, consistent with their mitochondrial dependence for proper function.
NDUFA13 contributes to the electron transfer pathway within complex I. The electron flow proceeds from NADH in the matrix, through the Fe-S clusters of the N-module, to ubiquinone in the membrane arm. NDUFA13's position in the complex allows it to influence this electron flow and potentially the coupling to proton pumping.
Complex I translocates four protons per NADH oxidized. The mechanism involves conformational changes that propagate from the N-module through the Q-module to the P-modules, which contain the proton channels. NDUFA13's structural role contributes to the proper coupling of these processes.
Complex I is a significant source of mitochondrial ROS, particularly under conditions of electron leak. The efficiency of electron transfer through complex I influences ROS production rates. NDUFA13 dysfunction may alter this balance and contribute to oxidative stress.
Understanding NDUFA13 function has several therapeutic implications:
Gene Therapy: For patients with NDUFA13 mutations, gene therapy approaches to restore proper complex I function are being explored.
Mitochondrial Protection: Strategies to protect mitochondrial function, including antioxidants and mitochondrial-targeted compounds, may benefit patients with complex I deficiency.
Apoptosis Modulation: Understanding NDUFA13's apoptotic function may lead to approaches to modulate neuronal survival in neurodegenerative diseases.
Metabolic Support: Providing alternative energy substrates, such as ketone bodies, may help compensate for complex I deficiency in neurons.
Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, Neumeister M, Lin H. GRIM-19, a death-regulatory gene product, sensitizes cancer cells to TRAIL-induced apoptosis. 2004. ↩︎
Sazanov LA. A giant molecular proton pump: structure and mechanism of respiratory complex I. 2015. ↩︎
Fiedorczuk K, Letts JA, Degliesposti G, Townsend JP, Sazanov LA. Atomic structure of the entire mammalian mitochondrial complex I. 2016. ↩︎ ↩︎
Guerrero-Castillo S, Baertling F, Kownatzki D, Wessels HJ, Arnold S, Brandt UB, Nijtmans LG. The assembly pathway of mitochondrial respiratory chain complex I. 2017. ↩︎
Angebault C, Boudria M, Chrétien D, Li L, Gouiran V, Lebigot S, R是什么人 N, Deltoquin M, Serre V, Rivier F, Goureau H, Amati-Bonneau P, Bonneau D, Reynier P, Procaccio V, Lenaers G,Fragaki K. Mitochondrial complex I deficiency caused by NDUFA13 mutations. 2018. ↩︎ ↩︎
Fearnley IM, Carroll J, Shannon RJ, Runswick MJ, Walker JE, Hirst J. GRIM-19: a mitochondrial protein that regulates cell death. 2004. ↩︎
Pryde KR, Hirst J. Mechanism of mitochondrial complex I reduction: implications for neurodegeneration. 2011. ↩︎
Lake NJ, Compton AG, Rahman S, Thorburn DR. Leigh syndrome: a genetic disorder of mitochondrial metabolism. 2016. ↩︎
Du H, Guo L, Yan S, Sosunov A, McKhann GM, Yan SS. Early deficits in mitochondrial function in Alzheimer disease. 2010. ↩︎
Riederer P, Jellinger KA, Kolter I, Riederer IM, Wollenweber FA, Zacharias R, Blanz K, Hermersdorfer H, Zierz S. Mitochondrial complex I deficiency in Parkinson disease. 2019. ↩︎